Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2  + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

ConclusionOur results showed high pCR rates with Trastuzumab and Pertuzumab associated to chemotherapy. They were similar in TOP2A  + and TOP2A- groups and the current role of neoadjuvant anthracycline-based chemotherapy remains questioned.Trial registration numberNCT02339532 (registered on 14/12/14).
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research